ArticleFrontiers in public health2025
Global, regional, and national burden of laryngeal cancer in middle-aged and older adults from 1990 to 2021: an analysis of age and sex differences and attributable risk factors.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Network pharmacology-guided identification of Rabdosia rubescent as a suppressor of laryngeal cancer via MMP9-mediated extracellular matrix remodeling: integratedFrontiers in pharmacology · 2026Article
- Global burden and cross-country inequalities in head and neck cancer from 1992 to 2021: results from the global burden of disease study.Health economics review · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal cancer (LC) is a prevalent head and neck tumor, yet few studies quantify its disease burden and trends in risk factors of the age subgroup of middle-aged and older adult people (MAOP). Methods: Based on Global Burden of Disease 2021 (GBD 2021) data, this study comprehensively assessed trends of disease burden in the age subgroup of LC in MAOP across 204 countries and regions from 1990 to 2021, covering incidence, prevalence, mortality, and disability-adjusted life years (DALYs). The estimated annual percentage change (EAPC) and joinpoint regression model were used to analyze the trends of disease burden and the changes in disease burden attributed to tobacco, alcohol, and occupational risk factors. Results: Worldwide, the number of LC in MAOP prevalence, incidence, mortality, and DALYs totaled 887,500, 163,300, 97,500, and 2,284,800 in 2021. Over the previous 32 years, the rates of these indicators declined, with EAPC of -0.62 (-0.69 to -0.55), -0.95 (-1.04 to -1.87), -1.52 (-1.6 to -1.43), and -1.69 (-1.79 to -1.59), respectively. Regions with high Sociodemographic Index (SDI) showed high prevalence and morbidity. Still, they had low mortality and DALY rates, whereas areas with low SDI, such as Sub-Saharan Africa, experienced high mortality and DALY rates. Central Europe, a high-middle SDI region, was a "hotspot" for laryngeal cancer. Before the age of 75, males showed a more significant burden of disease indicators, with a peak incidence rate of 28.05 (23.93, 30.47) per 100,000 individuals between the ages of 85 and 90. However, the 85-89 and 90-94 age groups saw rising prevalence rates. The main risk factor for LC-related deaths and DALY in MAOP was tobacco exposure, particularly in low-middle SDI regions. Conclusion: In the last 32 years, the burden of LC in MAOP has declined globally, yet age-related disparities and SDI stratification persist. Men aged before 75 and after 85 need to be targeted as key groups for prevention and control. Tobacco exposure was the leading risk factor, especially in low-middle SDI regions. These findings highlight the critical necessity for tailored public health strategies and policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.